Autism Spectrum Disorders (ASD) are a multifaceted set of neurodevelopmental disorders caused by diverse genetic, epigenetic and environmental factors. Epigenetic mechanisms such as DNA methylation regulate gene expression without changing the genomic DNA sequence, but changing how genomic information is interpreted. The identification of RNA molecules such as non-coding RNAs and its modifications such as RNA methylation as separate functional entities caused a paradigm shift in the epigenetic field. Recent advances have demonstrated that epigenetic mechanisms involving RNA molecules could be immensely contributing to the complex ASD pathobiology. Indirect evidence suggests that methylation of mRNA could be functioning as a regulatory switch in maintaining a balance between mRNA turnover and protein synthesis in autistic patients. Moreover, many studies provide supporting evidence that alterations to ‘the methylation cycle’, which extend to the methionine-homocysteine pathway, folate cycle, and the redox-homeostasis pathway could underwrite the reduced methylation capacity in ASD. This, in turn, may reduce the RNA methylation status in autistic patients. While implications of RNA methylation in ASD is intriguing, the direct role of RNA methylation in ASD pathogenesis is yet to be explored in depth. In contrast, the functional aspects of non-coding RNAs – both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) – in ASD have been investigated. MiRNAs found in the autistic brain, blood, saliva or lymphoblast cell lines have shown differential expression as well as deregulation of their target genes. These miRNAs and target genes are associated with synaptic processes, synaptic plasticity, memory, neuronal morphology as well as many cell signaling pathways which could be contributing to the pathobiology of ASD. Similarly, many lncRNAs are differentially expressed in autistic patients and are involved in the deregulation of neuronal connectivity, synaptic functions, and imprinting. Interestingly, some of these lncRNAs are associated with increased risk of ASD. Collectively, epigenetic mechanisms provide codes for maintenance of proper cellular functions. When these epigenetic mechanisms are miscoded, the altered expression of genes, cellular processes and functions contribute towards the pathogenesis of ASD. Therefore, understanding these miscoded RNA epigenetic mechanisms will hold promise for future therapeutic developments for ASD.
| Published in | Biomedical Sciences (Volume 2, Issue 4) |
| DOI | 10.11648/j.bs.20160204.11 |
| Page(s) | 24-33 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2016. Published by Science Publishing Group |
RNA Methylation, MicroRNA, Non-coding RNA
| [1] | N. T. Vijayakumar, M. V. Judy, Autism spectrum disorders: Integration of the genome, transcriptome and the environment. J Neurol Sci 364, 167 (May 15, 2016). |
| [2] | I. Voineagu, Gene expression studies in autism: moving from the genome to the transcriptome and beyond. Neurobiol Dis 45, 69 (Jan, 2012). |
| [3] | A. Zhubi, E. H. Cook, A. Guidotti, D. R. Grayson, Epigenetic mechanisms in autism spectrum disorder. Int Rev Neurobiol 115, 203 (2014). |
| [4] | V. R. B. Liyanage, R. M. Zachariah, G. P. Delcuve, J. R. Davie, M. Rastegar, in Advances in Genetics Research, K. V. Urbano, Ed. (Nova Science Publishers, 2015), vol. 13, pp. 57-88. |
| [5] | T. W. Nilsen, Molecular biology. Internal mRNA methylation finally finds functions. Science 343, 1207 (Mar 14, 2014). |
| [6] | Y. Yue, J. Liu, C. He, RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev 29, 1343 (Jul 1, 2015). |
| [7] | V. R. Liyanage et al., DNA modifications: function and applications in normal and disease States. Biology (Basel) 3, 670 (2014). |
| [8] | Y. Fu, D. Dominissini, G. Rechavi, C. He, Gene expression regulation mediated through reversible m (6) A RNA methylation. Nat Rev Genet 15, 293 (May, 2014). |
| [9] | F. Ye et al., Repair of methyl lesions in RNA by oxidative demethylation. MedChemComm 5, 1797 (2014). |
| [10] | N. Liu, T. Pan, RNA epigenetics. Transl Res 165, 28 (Jan, 2015). |
| [11] | V. R. B. Liyanage, R. M. Zachariah, G. P. Delcuve, J. R. Davie, M. Rastegar, in New Developments in Chromatin Research, N. M. Simpson, V. J. Stewart, Eds. (Nova Science Publishers 2012), pp. 29-58. |
| [12] | J. Cao, The functional role of long non-coding RNAs and epigenetics. Biol Proced Online 16, 11 (2014). |
| [13] | B. Wilkinson, D. B. Campbell, in International Review of Neurobiology, K. Genevieve, Ed. (Academic Press, 2013), vol. Volume 113, pp. 35-59. |
| [14] | T. Sado, N. Brockdorff, Advances in understanding chromosome silencing by the long non-coding RNA Xist. Philos Trans R Soc Lond B Biol Sci 368, 20110325 (Jan 5, 2013). |
| [15] | A. V. Ciernia, J. LaSalle, The landscape of DNA methylation amid a perfect storm of autism aetiologies. Nat Rev Neurosci, (May 6, 2016). |
| [16] | Y. J. Menezo, K. Elder, B. Dale, Link Between Increased Prevalence of Autism Spectrum Disorder Syndromes and Oxidative Stress, DNA Methylation, and Imprinting: The Impact of the Environment. JAMA Pediatr 169, 1066 (Nov, 2015). |
| [17] | C. Ladd-Acosta et al., Common DNA methylation alterations in multiple brain regions in autism. Mol Psychiatry 19, 862 (Aug, 2014). |
| [18] | M. S. Trivedi, R. C. Deth, Role of a redox-based methylation switch in mRNA life cycle (pre- and post-transcriptional maturation) and protein turnover: implications in neurological disorders. Front Neurosci 6, 92 (2012). |
| [19] | R. J. Kelleher, 3rd, M. F. Bear, The autistic neuron: troubled translation? Cell 135, 401 (Oct 31, 2008). |
| [20] | Y. Li et al., Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13, 446 (Oct 3, 2013). |
| [21] | F. Laumonnier, L. S. Nguyen, L. Jolly, M. Raynaud, J. Gecz, in Comprehensive Guide to Autism, B. V. Patel, R. V. Preedy, R. C. Martin, Eds. (Springer New York, New York, NY, 2014), pp. 1663-1678. |
| [22] | L. S. Nguyen, M. F. Wilkinson, J. Gecz, Nonsense-mediated mRNA decay: inter-individual variability and human disease. Neurosci Biobehav Rev 46 Pt 2, 175 (Oct, 2014). |
| [23] | K. L. Heilman, R. A. Leach, M. T. Tuck, Internal 6-methyladenine residues increase the in vitro translation efficiency of dihydrofolate reductase messenger RNA. Int J Biochem Cell Biol 28, 823 (Jul, 1996). |
| [24] | M. Caboche, J. P. Bachellerie, RNA methylation and control of eukaryotic RNA biosynthesis. Effects of cycloleucine, a specific inhibitor of methylation, on ribosomal RNA maturation. Eur J Biochem 74, 19 (Mar 15, 1977). |
| [25] | S. J. James et al., Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80, 1611 (Dec, 2004). |
| [26] | S. J. James et al., Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 141 B, 947 (Dec 5, 2006). |
| [27] | L. Abbasi-Moheb et al., Mutations in NSUN2 cause autosomal-recessive intellectual disability. Am J Hum Genet 90, 847 (May 4, 2012). |
| [28] | J. Liu, G. Jia, Methylation modifications in eukaryotic messenger RNA. J Genet Genomics 41, 21 (Jan 20, 2014). |
| [29] | O. D. Maddocks, C. F. Labuschagne, P. D. Adams, K. H. Vousden, Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells. Mol Cell 61, 210 (Jan 21, 2016). |
| [30] | O. Tehlivets, N. Malanovic, M. Visram, T. Pavkov-Keller, W. Keller, S-adenosyl-L-homocysteine hydrolase and methylation disorders: yeast as a model system. Biochim Biophys Acta 1832, 204 (Jan, 2013). |
| [31] | V. Khoddami, B. R. Cairns, Transcriptome-wide target profiling of RNA cytosine methyltransferases using the mechanism-based enrichment procedure Aza-IP. Nat. Protocols 9, 337 (2014). |
| [32] | S. Melnyk et al., Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism. J Autism Dev Disord 42, 367 (Mar, 2012). |
| [33] | Y. M. Al-Farsi et al., Low folate and vitamin B12 nourishment is common in Omani children with newly diagnosed autism. Nutrition 29, 537 (Mar, 2013). |
| [34] | R. J. Leeming, M. Lucock, Autism: Is there a folate connection? J Inherit Metab Dis 32, 400 (Jun, 2009). |
| [35] | C. R. Muratore et al., Age-Dependent Decrease and Alternative Splicing of Methionine synthase mRNA in Human Cerebral Cortex and an Accelerated Decrease in Autism. PLoS ONE 8, e56927 (2013). |
| [36] | A. Ghanizadeh et al., Glutathione-related factors and oxidative stress in autism, a review. Curr Med Chem 19, 4000 (2012). |
| [37] | R. Deth, C. Muratore, J. Benzecry, V. A. Power-Charnitsky, M. Waly, How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. Neurotoxicology 29, 190 (Jan, 2008). |
| [38] | R. Deth, C. Muratore, J. Benzecry, V.-A. Power-Charnitsky, M. Waly, How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. NeuroToxicology 29, 190 (2008). |
| [39] | S. Rose et al., Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry 2, e134 (2012). |
| [40] | A. Chauhan, T. Audhya, V. Chauhan, Brain region-specific glutathione redox imbalance in autism. Neurochem Res 37, 1681 (Aug, 2012). |
| [41] | R. L. Stone et al., A mutation in adenylosuccinate lyase associated with mental retardation and autistic features. Nat Genet 1, 59 (Apr, 1992). |
| [42] | M. R. Redinbo, S. M. Eide, R. L. Stone, J. E. Dixon, T. O. Yeates, Crystallization and preliminary structural analysis of Bacillus subtilis adenylosuccinate lyase, an enzyme implicated in infantile autism. Protein Sci 5, 786 (Apr, 1996). |
| [43] | E. A. Fon et al., Adenylosuccinate lyase (ADSL) and infantile autism: absence of previously reported point mutation. Am J Med Genet 60, 554 (Dec 18, 1995). |
| [44] | A. Anitha, I. Thanseem, microRNA and Autism. Adv Exp Med Biol 888, 71 (2015). |
| [45] | I. Voineagu et al., Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 474, 380 (Jun 16, 2011). |
| [46] | S. Gupta et al., Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun 5, 5748 (2014). |
| [47] | B. P. Ander, N. Barger, B. Stamova, F. R. Sharp, C. M. Schumann, Atypical miRNA expression in temporal cortex associated with dysregulation of immune, cell cycle, and other pathways in autism spectrum disorders. Mol Autism 6, 37 (2015). |
| [48] | M. M. Ghahramani Seno et al., Gene and miRNA expression profiles in autism spectrum disorders. Brain Research 1380, 85 (2011). |
| [49] | M. Marrale, N. N. Albanese, F. Calì, V. Romano, Assessing the Impact of Copy Number Variants on miRNA Genes in Autism by Monte Carlo Simulation. PLoS ONE 9, e90947 (2014). |
| [50] | F. Huang et al., Investigation of Gene Regulatory Networks Associated with Autism Spectrum Disorder Based on MiRNA Expression in China. PLoS ONE 10, e0129052 (2015). |
| [51] | K. Abu-Elneel et al., Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 9, 153 (Jul, 2008). |
| [52] | T. Sarachana, R. Zhou, G. Chen, H. K. Manji, V. W. Hu, Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Medicine 2, 1 (2010). |
| [53] | T. Sarachana, V. W. Hu, in Frontiers in Autism Research: New Horizons for Diagnosis and Treatment. (2014), pp. 175-202. |
| [54] | X. F. Jin, N. Wu, L. Wang, J. Li, Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol 33, 601 (Jul, 2013). |
| [55] | M. Mundalil Vasu et al., Serum microRNA profiles in children with autism. Mol Autism 5, 40 (2014). |
| [56] | S. D. Hicks, C. Ignacio, K. Gentile, F. A. Middleton, Salivary miRNA profiles identify children with autism spectrum disorder, correlate with adaptive behavior, and implicate ASD candidate genes involved in neurodevelopment. BMC Pediatr 16, 52 (2016). |
| [57] | Z. Talebizadeh, M. G. Butler, M. F. Theodoro, Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Research 1, 307 (2008). |
| [58] | K. Abu-Elneel et al., Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 9, 153 (2008). |
| [59] | Z. Yang et al., Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol 51, 823 (Oct, 2014). |
| [60] | C. R. Alarcon, H. Lee, H. Goodarzi, N. Halberg, S. F. Tavazoie, N6-methyladenosine marks primary microRNAs for processing. Nature 519, 482 (Mar 26, 2015). |
| [61] | T. Berulava, S. Rahmann, K. Rademacher, L. Klein-Hitpass, B. Horsthemke, N6-Adenosine Methylation in MiRNAs. PLoS ONE 10, e0118438 (2015). |
| [62] | D. E. Kuhn et al., Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem Biophys Res Commun 370, 473 (Jun 6, 2008). |
| [63] | L. S. Nguyen et al., Profiling olfactory stem cells from living patients identifies miRNAs relevant for autism pathophysiology. Mol Autism 7, 1 (2016). |
| [64] | L. Lipovich et al., Activity-dependent human brain coding/noncoding gene regulatory networks. Genetics 192, 1133 (Nov, 2012). |
| [65] | W. T. Powell et al., A Prader-Willi locus lncRNA cloud modulates diurnal genes and energy expenditure. Hum Mol Genet 22, 4318 (Nov 1, 2013). |
| [66] | M. N. Ziats, O. M. Rennert, Aberrant expression of long noncoding RNAs in autistic brain. J Mol Neurosci 49, 589 (Mar, 2013). |
| [67] | Y. Wang et al., Genome-wide differential expression of synaptic long noncoding RNAs in autism spectrum disorder. Transl Psychiatry 5, e660 (2015). |
| [68] | T. Kerin et al., A noncoding RNA antisense to moesin at 5 p14.1 in autism. Sci Transl Med 4, 128 ra40 (Apr 4, 2012). |
| [69] | B. Gudenas, L. Wang, Identification of Autism Spectrum Disorders associated Long Non-Coding RNAs shows connections to the synaptic transmission pathway. (2015). |
| [70] | J. B. Vincent et al., The RAY1/ST7 tumor-suppressor locus on chromosome 7 q 31 represents a complex multi-transcript system. Genomics 80, 283 (Sep, 2002). |
| [71] | V. van de, II et al., Long non-coding RNAs in neurodevelopmental disorders. Front Mol Neurosci 6, 53 (2013). |
| [72] | D. Velmeshev, M. Magistri, M. A. Faghihi, Expression of non-protein-coding antisense RNAs in genomic regions related to autism spectrum disorders. Molecular Autism 4, 1 (2013). |
| [73] | G. Cao, H. B. Li, Z. Yin, R. A. Flavell, Recent advances in dynamic m6A RNA modification. Open Biol 6, (Apr, 2016). |
| [74] | D. Dominissini et al., Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485, 201 (May 10, 2012). |
| [75] | G. Jia et al., N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 7, 885 (Dec, 2011). |
| [76] | T. Amort et al., Long non-coding RNAs as targets for cytosine methylation. RNA Biol 10, 1003 (Jun, 2013). |
| [77] | Z. Talebizadeh, M. G. Butler, M. F. Theodoro, Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Res 1, 240 (Aug, 2008). |
| [78] | T. Sarachana, R. Zhou, G. Chen, H. K. Manji, V. W. Hu, Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med 2, 23 (2010). |
| [79] | N. Mellios, M. Sur, The Emerging Role of microRNAs in Schizophrenia and Autism Spectrum Disorders. Front Psychiatry 3, 39 (2012). |
APA Style
Vichithra Rasangi Batuwita Liyanage. (2016). Role of RNA Methylation and Non-Coding RNAs in Pathobiology of Autism Spectrum Disorders. Biomedical Sciences, 2(4), 24-33. https://doi.org/10.11648/j.bs.20160204.11
ACS Style
Vichithra Rasangi Batuwita Liyanage. Role of RNA Methylation and Non-Coding RNAs in Pathobiology of Autism Spectrum Disorders. Biomed. Sci. 2016, 2(4), 24-33. doi: 10.11648/j.bs.20160204.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.bs.20160204.11,
author = {Vichithra Rasangi Batuwita Liyanage},
title = {Role of RNA Methylation and Non-Coding RNAs in Pathobiology of Autism Spectrum Disorders},
journal = {Biomedical Sciences},
volume = {2},
number = {4},
pages = {24-33},
doi = {10.11648/j.bs.20160204.11},
url = {https://doi.org/10.11648/j.bs.20160204.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bs.20160204.11},
abstract = {Autism Spectrum Disorders (ASD) are a multifaceted set of neurodevelopmental disorders caused by diverse genetic, epigenetic and environmental factors. Epigenetic mechanisms such as DNA methylation regulate gene expression without changing the genomic DNA sequence, but changing how genomic information is interpreted. The identification of RNA molecules such as non-coding RNAs and its modifications such as RNA methylation as separate functional entities caused a paradigm shift in the epigenetic field. Recent advances have demonstrated that epigenetic mechanisms involving RNA molecules could be immensely contributing to the complex ASD pathobiology. Indirect evidence suggests that methylation of mRNA could be functioning as a regulatory switch in maintaining a balance between mRNA turnover and protein synthesis in autistic patients. Moreover, many studies provide supporting evidence that alterations to ‘the methylation cycle’, which extend to the methionine-homocysteine pathway, folate cycle, and the redox-homeostasis pathway could underwrite the reduced methylation capacity in ASD. This, in turn, may reduce the RNA methylation status in autistic patients. While implications of RNA methylation in ASD is intriguing, the direct role of RNA methylation in ASD pathogenesis is yet to be explored in depth. In contrast, the functional aspects of non-coding RNAs – both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) – in ASD have been investigated. MiRNAs found in the autistic brain, blood, saliva or lymphoblast cell lines have shown differential expression as well as deregulation of their target genes. These miRNAs and target genes are associated with synaptic processes, synaptic plasticity, memory, neuronal morphology as well as many cell signaling pathways which could be contributing to the pathobiology of ASD. Similarly, many lncRNAs are differentially expressed in autistic patients and are involved in the deregulation of neuronal connectivity, synaptic functions, and imprinting. Interestingly, some of these lncRNAs are associated with increased risk of ASD. Collectively, epigenetic mechanisms provide codes for maintenance of proper cellular functions. When these epigenetic mechanisms are miscoded, the altered expression of genes, cellular processes and functions contribute towards the pathogenesis of ASD. Therefore, understanding these miscoded RNA epigenetic mechanisms will hold promise for future therapeutic developments for ASD.},
year = {2016}
}
TY - JOUR T1 - Role of RNA Methylation and Non-Coding RNAs in Pathobiology of Autism Spectrum Disorders AU - Vichithra Rasangi Batuwita Liyanage Y1 - 2016/08/27 PY - 2016 N1 - https://doi.org/10.11648/j.bs.20160204.11 DO - 10.11648/j.bs.20160204.11 T2 - Biomedical Sciences JF - Biomedical Sciences JO - Biomedical Sciences SP - 24 EP - 33 PB - Science Publishing Group SN - 2575-3932 UR - https://doi.org/10.11648/j.bs.20160204.11 AB - Autism Spectrum Disorders (ASD) are a multifaceted set of neurodevelopmental disorders caused by diverse genetic, epigenetic and environmental factors. Epigenetic mechanisms such as DNA methylation regulate gene expression without changing the genomic DNA sequence, but changing how genomic information is interpreted. The identification of RNA molecules such as non-coding RNAs and its modifications such as RNA methylation as separate functional entities caused a paradigm shift in the epigenetic field. Recent advances have demonstrated that epigenetic mechanisms involving RNA molecules could be immensely contributing to the complex ASD pathobiology. Indirect evidence suggests that methylation of mRNA could be functioning as a regulatory switch in maintaining a balance between mRNA turnover and protein synthesis in autistic patients. Moreover, many studies provide supporting evidence that alterations to ‘the methylation cycle’, which extend to the methionine-homocysteine pathway, folate cycle, and the redox-homeostasis pathway could underwrite the reduced methylation capacity in ASD. This, in turn, may reduce the RNA methylation status in autistic patients. While implications of RNA methylation in ASD is intriguing, the direct role of RNA methylation in ASD pathogenesis is yet to be explored in depth. In contrast, the functional aspects of non-coding RNAs – both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) – in ASD have been investigated. MiRNAs found in the autistic brain, blood, saliva or lymphoblast cell lines have shown differential expression as well as deregulation of their target genes. These miRNAs and target genes are associated with synaptic processes, synaptic plasticity, memory, neuronal morphology as well as many cell signaling pathways which could be contributing to the pathobiology of ASD. Similarly, many lncRNAs are differentially expressed in autistic patients and are involved in the deregulation of neuronal connectivity, synaptic functions, and imprinting. Interestingly, some of these lncRNAs are associated with increased risk of ASD. Collectively, epigenetic mechanisms provide codes for maintenance of proper cellular functions. When these epigenetic mechanisms are miscoded, the altered expression of genes, cellular processes and functions contribute towards the pathogenesis of ASD. Therefore, understanding these miscoded RNA epigenetic mechanisms will hold promise for future therapeutic developments for ASD. VL - 2 IS - 4 ER -
Information
Email: